TReatment by Insulin Continuous Infusion in Type 2 DIAbetes

• Status: Unknown status
• Trial end date: 2015-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the TRICIDIA2 study is to compare two modalities of administration of insulin.

In our future study, the investigators wish to study if the treatment by continuous infusion of insulin improves the insulinosensitivity of type 2 diabetic patients; the investigators indeed expect that the insulin delivered in a continuous way decreases the insulino-resistance of these patients compared with the intermittent delivering of insulin.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Hospitalier Universitaire Dijon
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• age > 18 years old

• type 2 diabete patient with insuline basal/bolus treatment for at least 6 months

• Doses of insuline > 0,7 U/Kg/j

• HbA1c ≥ 7,5%

• without ADO for at least 4 weeks (sulfamides, Incrétines, glinides, acarbose) except the metformine

• BMI ≥ 28,5 kg/m²

• clinical diagnostique of diabetes for at least 10 ans

• Patient must be able to Realize an automonitoring and to manage the functioning of an insulin pump.

Exclusion Criteria:

• glitazone treatment less than 3 month before inclusion

• Patient with an untreated by the laser proliferative ischemic retinopathy

• BMI < 28,5 kg/m²

• Pacemaker (CI IRM)

• Presence of implantable material (CI IRM)

• Pregnancy, breast-feeding

• Practices of violent sports

• Professional extreme environment of cold or heat

• Serious psychiatric diseases physical and/or psychiatric Incapacitated medically significant

• Poor sanitation